Literature DB >> 560072

A neutralization test survey for Lassa Fever activity in Lassa, Nigeria.

R B Arnold, G W Gary.   

Abstract

5-8% of 434 sera collected in Lassa village, Nigeria, in August 1970 were positive by neutralization test for Lassa fever (LF) virus. A second survey in March 1971 found 15 of 47 complete compounds tested in Lassa, Dille and Yuba villages had at least one peron with serologically demonstrable experience with LF virus. 67% of positive compounds had more than one infected member. Four of 17 hospital staff sero-converted between August 1970 and March 1971 without symptoms, evidence that subclinical infections of LF occr.

Entities:  

Mesh：

Year:  1977        PMID： 560072     DOI： 10.1016/0035-9203(77)90085-2

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


  4 in total

1.  Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation.

Authors:  D G Bausch; P E Rollin; A H Demby; M Coulibaly; J Kanu; A S Conteh; K D Wagoner; L K McMullan; M D Bowen; C J Peters; T G Ksiazek
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

2.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

Review 3.  Improving the Breadth of the Host's Immune Response to Lassa Virus.

Authors:  Juan Carlos Zapata; Sandra Medina-Moreno; Camila Guzmán-Cardozo; Maria S Salvato
Journal:  Pathogens       Date:  2018-10-28

4.  Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.

Authors:  Megan L Heinrich; Matthew L Boisen; Diana K S Nelson; Duane J Bush; Robert W Cross; Anatoliy P Koval; Andrew R Hoffmann; Brandon J Beddingfield; Kathryn M Hastie; Megan M Rowland; Irina Aimukanova; Sophia Koval; Raju Lathigra; Viktoriya Borisevich; Mambu Momoh; John Demby Sandi; Augustine Goba; Lkponmwosa Odia; Francis Baimba; John O Aiyepada; Benevolence Ebo; Philomena Eromon; Chinedu Ugwu; Onikepe Folarin; Testimony Olumade; MacDonald N Onyechi; Johnson Etafo; Rashidat Adeyemi; Elijah E Ella; Maryam Aminu; Simji S Gomerep; Matthew Afam Eke; Olusola Ogunsanya; George O Akpede; Danny O Asogun; Sylvanus A Okogbenin; Peter O Okokhere; Johan Holst; Jeffrey G Shaffer; John S Schieffelin; Thomas W Geisbert; Erica Ollmann Saphire; Christian T Happi; Donald S Grant; Robert F Garry; Luis M Branco
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.